241 related articles for article (PubMed ID: 19841143)
21. Antifungal susceptibility of bloodstream Candida isolates in Sfax hospital: Tunisia.
Sellami A; Sellami H; Néji S; Makni F; Abbes S; Cheikhrouhou F; Chelly H; Bouaziz M; Hammami B; Ben Jemaa M; Khaled S; Ayadi A
Mycopathologia; 2011 Jun; 171(6):417-22. PubMed ID: 21170738
[TBL] [Abstract][Full Text] [Related]
22. Generation of mutants in Candida albicans with reduced susceptibility to caspofungin: influence on other antifungal products.
Soler L; Rodriguez JC; Belda S; Cremades R; Ruiz-Garcia M; Lopez P; Royo G
J Chemother; 2010 Aug; 22(4):283-4. PubMed ID: 20685636
[No Abstract] [Full Text] [Related]
23. In vitro synergistic antifungal activities of caspofungin in combination with fluconazole or voriconazole against Candida species determined by the Etest method.
Yang Q; Liu Z; Wang Y; Xie J; Zhang K; Dong Y; Wang YF
Int J Infect Dis; 2022 Sep; 122():982-990. PubMed ID: 35907476
[TBL] [Abstract][Full Text] [Related]
24. [Study on in vitro susceptibility of Candida spp. isolated from blood culture].
Grandesso S; Sapino B; Mazzuccato S; Solinas M; Bedin M; D'Angelo M; Gion M
Infez Med; 2012 Mar; 20(1):25-30. PubMed ID: 22475657
[TBL] [Abstract][Full Text] [Related]
25. Interaction of the echinocandin caspofungin with amphotericin B or voriconazole against Aspergillus biofilms in vitro.
Liu W; Li L; Sun Y; Chen W; Wan Z; Li R; Liu W
Antimicrob Agents Chemother; 2012 Dec; 56(12):6414-6. PubMed ID: 23027186
[TBL] [Abstract][Full Text] [Related]
26. In vitro antifungal combination effects of micafungin with fluconazole, voriconazole, amphotericin B, and flucytosine against clinical isolates of Candida species.
Nishi I; Sunada A; Toyokawa M; Asari S; Iwatani Y
J Infect Chemother; 2009 Feb; 15(1):1-5. PubMed ID: 19280292
[TBL] [Abstract][Full Text] [Related]
27. Candida and candidaemia. Susceptibility and epidemiology.
Arendrup MC
Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246
[TBL] [Abstract][Full Text] [Related]
28. Broth microdilution and time-kill testing of Caspofungin, voriconazole, amphotericin B and their combinations against clinical isolates of Candida krusei.
Oz Y; Dag I; Kiraz N
Mycopathologia; 2012 Jan; 173(1):27-34. PubMed ID: 21842180
[TBL] [Abstract][Full Text] [Related]
29. In vitro activity of a novel broad-spectrum antifungal, E1210, tested against Candida spp. as determined by CLSI broth microdilution method.
Pfaller MA; Hata K; Jones RN; Messer SA; Moet GJ; Castanheira M
Diagn Microbiol Infect Dis; 2011 Oct; 71(2):167-70. PubMed ID: 21696907
[TBL] [Abstract][Full Text] [Related]
30. Mechanisms of azole resistance among clinical isolates of Candida glabrata in Poland.
Szweda P; Gucwa K; Romanowska E; Dzierz Anowska-Fangrat K; Naumiuk Ł; Brillowska-Da Browska A; Wojciechowska-Koszko I; Milewski S
J Med Microbiol; 2015 Jun; 64(6):610-619. PubMed ID: 25818698
[TBL] [Abstract][Full Text] [Related]
31. Antifungal susceptibility and virulence attributes of bloodstream isolates of Candida from Hong Kong and Finland.
Seneviratne CJ; Wong SS; Yuen KY; Meurman JH; Pärnänen P; Vaara M; Samaranayake LP
Mycopathologia; 2011 Nov; 172(5):389-95. PubMed ID: 21744043
[TBL] [Abstract][Full Text] [Related]
32. In vitro activity of voriconazole and other antifungal agents against clinical isolates of Candida glabrata and Candida krusei.
Drago M; Scaltrito MM; Morace G;
Eur J Clin Microbiol Infect Dis; 2004 Aug; 23(8):619-24. PubMed ID: 15258831
[TBL] [Abstract][Full Text] [Related]
33. Acquisition of flucytosine, azole, and caspofungin resistance in Candida glabrata bloodstream isolates serially obtained from a hematopoietic stem cell transplant recipient.
Chapeland-Leclerc F; Hennequin C; Papon N; Noël T; Girard A; Socié G; Ribaud P; Lacroix C
Antimicrob Agents Chemother; 2010 Mar; 54(3):1360-2. PubMed ID: 20038613
[TBL] [Abstract][Full Text] [Related]
34. Antifungal activity against Candida albicans of nikkomycin Z in combination with caspofungin, voriconazole or amphotericin B.
Sandovsky-Losica H; Shwartzman R; Lahat Y; Segal E
J Antimicrob Chemother; 2008 Sep; 62(3):635-7. PubMed ID: 18490373
[No Abstract] [Full Text] [Related]
35. Activity of caspofungin and voriconazole against clinical isolates of Candida and other medically important yeasts by the CLSI M-44A disk diffusion method with Neo-Sensitabs tablets.
Carrillo-Muñoz AJ; Quindós G; del Valle O; Santos P; Giusiano G; Ezkurra PA; Estivill MD; Casals JB
Chemotherapy; 2008; 54(1):38-42. PubMed ID: 18073469
[TBL] [Abstract][Full Text] [Related]
36. In vitro activities of voriconazole as a triazole derivative and caspofungin as an echinocandin were compared with those of some antifungal agents against Candida species isolated from clinical specimens.
Ozçelik B; Kaynak F; Cesur S; Sipahi B; Sultan N
Jpn J Infect Dis; 2007 Sep; 60(5):302-4. PubMed ID: 17881873
[TBL] [Abstract][Full Text] [Related]
37. Frequency of decreased susceptibility and resistance to echinocandins among fluconazole-resistant bloodstream isolates of Candida glabrata.
Pfaller MA; Castanheira M; Lockhart SR; Ahlquist AM; Messer SA; Jones RN
J Clin Microbiol; 2012 Apr; 50(4):1199-203. PubMed ID: 22278842
[TBL] [Abstract][Full Text] [Related]
38.
Fakhim H; Chowdhary A; Prakash A; Vaezi A; Dannaoui E; Meis JF; Badali H
Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28848002
[TBL] [Abstract][Full Text] [Related]
39. Unexpected effects of azole transporter inhibitors on antifungal susceptibility in Candida glabrata and other pathogenic Candida species.
Nagayoshi Y; Miyazaki T; Shimamura S; Nakayama H; Minematsu A; Yamauchi S; Takazono T; Nakamura S; Yanagihara K; Kohno S; Mukae H; Izumikawa K
PLoS One; 2017; 12(7):e0180990. PubMed ID: 28700656
[TBL] [Abstract][Full Text] [Related]
40. Identification and antifungal susceptibility of Candida species isolated from bloodstream infections in Konya, Turkey.
Dagi HT; Findik D; Senkeles C; Arslan U
Ann Clin Microbiol Antimicrob; 2016 May; 15(1):36. PubMed ID: 27245756
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
